Introduction: Accurate image segmentation is crucial in medical imaging for quantifying diseases, assessing prognosis, and evaluating treatment outcomes. However, existing methods often fall short in integrating global and local features in a meaningful way, failing to give sufficient attention to abnormal regions and boundary details in medical images. These limitations hinder the effectiveness of segmentation techniques in clinical settings. To address these issues, we propose a novel deep learning-based approach, MIPC-Net, designed for precise boundary segmentation in medical images.
Methods: Our approach, inspired by radiologists' working patterns, introduces two distinct modules: 1. Mutual Inclusion of Position and Channel Attention (MIPC) Module: To improve boundary segmentation precision, we present the MIPC module. This module enhances the focus on channel information while extracting position features and vice versa, effectively enhancing the segmentation of boundaries in medical images. 2. Skip-Residue Module: To optimize the restoration of medical images, we introduce Skip-Residue, a global residual connection. This module improves the integration of the encoder and decoder by filtering out irrelevant information and recovering the most crucial information lost during the feature extraction process.
Results: We evaluate the performance of MIPC-Net on three publicly accessible datasets: Synapse, ISIC2018-Task, and Segpc. The evaluation uses metrics such as the Dice coefficient (DSC) and Hausdorff Distance (HD). Our ablation study confirms that each module contributes to the overall improvement of segmentation quality. Notably, with the integration of both modules, our model outperforms state-of-the-art methods across all metrics. Specifically, MIPC-Net achieves a 2.23 mm reduction in Hausdorff Distance on the Synapse dataset, highlighting the model's enhanced capability for precise image boundary segmentation.
Conclusion: The introduction of the novel MIPC and Skip-Residue modules significantly improves feature extraction accuracy, leading to better boundary recognition in medical image segmentation tasks. Our approach demonstrates substantial improvements over existing methods, as evidenced by the results on benchmark datasets.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704489 | PMC |
http://dx.doi.org/10.3389/fbioe.2024.1504249 | DOI Listing |
Alzheimers Dement
December 2024
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.
Background: Effective early intervention of mild cognitive impairment (MCI) is the key for preventing dementia. However, there is currently no drug for MCI. As a multi-targeted neuroprotective agent, butylphthalide has been demonstrated to repair cognition in patients with vascular cognitive impairment, and has the potential to treat MCI due to Alzheimer's disease (AD).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China.
Background: Cerebral small vessel disease (CSVD) is one of the most common nervous system diseases. Hypertension and neuroinflammation are considered important risk factors for the development of CSVD and white matter (WM) lesions.
Method: We used the spontaneously hypertensive rat (SHR) as a model of early-onset CSVD and administered epimedium flavonoids (EF) for three months.
Alzheimers Dement
December 2024
University of California San Francisco (UCSF), San Francisco, CA, USA; Northern California Institute for Research & Education (NCIRE), San Francisco, CA, USA; San Francisco Veterans Administration Medical Center (SFVAMC), San Francisco, CA, CA, USA.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) has made many important contributions to the development of Alzheimer's Disease (AD) disease modifying treatments and diagnostic biomarkers. Since its funding in 2004 by the National Institutes of Aging, the goal of ADNI has been the validation of biomarkers for AD treatment trials. ADNI has enrolled over 2,400 participants in the USA and Canada for longitudinal clinical, cognitive, and biomarker studies.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Autonomous University of Barcelona, Barcelona, Catalonia, Spain.
Background: Alzheimer's and related disorders (ADRD) represent a range of neurodegenerative conditions characterized by abnormal protein deposits in the brain. Despite advances, there is a need for enhanced diagnostic and treatment approaches that acknowledge the diversity of ADRD. This project introduces the Alzheimer's and Related Disorders Multicenter Archive (ARMA), a collaborative platform with an advanced Electronic Data Capture (EDC) system linked to Electronic Medical Records (EMR) designed to refine ADRD diagnosis and natural history understanding, thus informing precision medicine.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
In Japan, the regulatory authority approved the drug in September 2023, and on December 20, it became available for prescription country-wide under the health insurance system. However, there are strict patient, physician, and facility requirements for the prescription of Lecanemab, and various problems are anticipated in its future implementation and widespread use in society. Lecanemab is the first anti-Aβ antibody in Japan, and even dementia specialists do not have sufficient knowledge and experience in its introduction, evaluation of efficacy, and evaluation and handling of side effects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!